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Eleven years ago, a 27-year-old non-drug abuser woman was admitted to the hospital due to a burn injury. During
the treatment, she was diagnosed with tricuspid valve infective endocarditis caused by multi-drug resistant (MDR)
Pseudomonas aeruginosa (P. aeruginosa). She underwent tricuspid valve replacement (TVR) using a bioprosthetic
valve, followed by 6 weeks of meropenem antibiotic therapy. Ten years later, she was again diagnosed with prosthetic
valve infective endocarditis caused by MDR P. aeruginosa. She underwent redo-TVR with a bioprosthetic valve and was
treated with colistin and ciprofloxacin. Ten months later, she was again diagnosed with prosthetic valve infective
endocarditis with MDR P. aeruginosa as a pathogen. She underwent a second redo-TVR with a tissue valve
and was treated with colistin. Two months later, her fever recurred and she was again diagnosed with prosthetic
valve infective endocarditis caused by MDR P. aeruginosa. She eventually underwent a third redo-TVR using an aortic
valve homograft and was discharged from the hospital after additional 6 weeks’ of antibiotic therapy. All the strains
of P. aeruginosa isolated from each event of infective endocarditis were analyzed by repetitive deoxyribonucleic acid
sequence-based polymerase chain reaction (rep-PCR) deoxyribonucleic acid (DNA) strain typing to determine the
correlation of isolates. All of the pathogens in 11 years were similar enough to be classified as the same strain, and this
is the first case report of TVR using an aortic valve homograft to treat relapsing endocarditis.
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Repeat infective endocarditis due to the same species is
traditionally defined as a “relapse” if the second episode
of infective endocarditis occurs within 6 months after
the initial episode, but is defined as a “recurrence” if the
second episode occurs after a period greater than 6
months from the previous episode. However, if a repeat
episode of infective endocarditis is shown by molecular
analysis to be caused by the same strain, it would be bet-
ter defined as a “relapse” regardless of the time duration
between episodes [1].* Correspondence: kimkb@snu.ac.kr
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Eleven years ago, a 27-year-old non-drug abuser woman
was hospitalized due to a major burn injuring 55 % of
her total body surface area. During her hospital treatment,
she developed a sustained fever. Blood cultures revealed
multi-drug resistant (MDR) Pseudomonas aeruginosa
(P. aeruginosa) bacteremia. Her fever did not subside in
spite of antibiotic therapy, and an echocardiogram showed
tricuspid valve vegetation. She was transferred to our hos-
pital and underwent tricuspid valve replacement (TVR)
with a porcine bioprosthetic valve (27 mm Hancock II mi-
tral valve; Medtronic, Minneapolis, MN). Her intraopera-
tive valvular tissue cultures also proved to be positive for
P. aeruginosa. She was treated with carbapenem antibi-
otics (meropenem) for 6 additional weeks after surgery
and her blood cultures after the surgery revealed no bac-
terial growth. Ten years later, she developed symptoms ofle distributed under the terms of the Creative Commons Attribution License
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MDR P. aeruginosa was grown from her blood cultures
and her echocardiogram revealed tricuspid valve vegeta-
tion with paravalvular leakage. She was initially treated
with polymyxin antibiotics (colistimethate sodium; colis-
tin), and underwent redo-TVR with a porcine biopros-
thetic valve (25 mm St. Jude Medical Epic valve; St. Jude
Medical, St. Paul, MN). Her valvular tissue cultures were
negative for P. aeruginosa. She received colistin and cipro-
floxacin antibiotic therapy for 6 weeks after surgery and
her postoperative blood cultures were shown to be nega-
tive for bacterial growth. Ten months later, she presented
at the hospital again with symptoms of fever and chills.
MDR P. aeruginosa was identified again by blood culture,
and her echocardiogram revealed vegetation on the pros-
thetic tricuspid valve, with abscess formation in the peri-
valvular area. Despite 6 weeks of antibiotic therapy with
colistin, her blood culture results remained positive for
P. aeruginosa and her spiking fever persisted. She under-
went a second redo-TVR with a bovine bioprosthetic
valve (25 mm Carpentier-Edward Perimount; Edwards
Lifesciences, Irvine, CA). Tissue cultures from the explanted
valve proved to be positive for P. aeruginosa, and she was
scheduled for treatment with colistin for 6 additional
weeks after surgery. However, she developed a fever on
postoperative day 39 and her blood culture results again
showed MDR P. aeruginosa growth. She then was treated
with colistin, ciprofloxacin and rifampin; however, her
blood cultures were still positive for P. aeruginosa and her
echocardiogram revealed vegetation on the bioprosthetic
valve. Two months after the second redo surgery, she
underwent a third redo-TVR with an aortic valve homo-
graft (23 mm) because a mitral valve homograft was not
available. Operative findings demonstrated abscessed and
necrotic tissues in the septal annular area of the prosthetic
valve stent although there was no prosthetic valve dehis-
cence. Abscessed and necrotic tissues were thoroughly re-
moved. Although a 25 mm sized bioprosthetic valve was
used in the previous second redo-TVR, a 23 mm sized
aortic valve homograft fitted on the tricuspid annulus well.
The aortic valve homograft was tailored appropriately,
and the proper location for anchoring the homograft com-
missures was identified in the right ventricular wall so that
the right ventricular outflow tract would align with one of
the valve sinuses. The fixation sutures for anchoring the
homograft commissures were placed on the septal, anter-
ior, and posteroinferior walls of the right ventricle using
interrupted 4-0 polypropylene sutures. The aortic valve
homograft was placed in the infra-annular position of
the tricuspid annulus, and the tricuspid annulus base
was exposed so that the previous abscess site was not con-
cealed by annular sewing sutures. Continuous 4-0 poly-
propylene suture was placed between the infra-annular
right ventricular position of the tricuspid annulus and thehomograft aortic valve annulus. Her intraoperative tissue
cultures did not reveal any bacterial growth. She received
continuous administration of the same antibiotics, and her
postoperative blood cultures were negative for bacterial
growth. She was discharged from the hospital after 6 add-
itional weeks of antibiotic therapy. The echocardiogram
performed before her discharge showed a well-functioning
homograft (Fig. 1), and she has been fever-free for more
than 12 months at an out-patient clinic.
In the present case, we identified the strains of each
pathogen involved in each event of infective endocarditis
by using the automated repetitive sequence-based poly-
merase chain reaction (rep-PCR) analysis method. This
method targets non-coding repetitive sequences which
are spread throughout eubacterial genomes [2], and has
been shown to be reliable on P. aeruginosa isolates [3].
Pathogens from each event of the patient’s infective endo-
carditis were frozen and stored at −80 °C, and maintained
at Microbank (Pro-Lab Diagnostics, Ontario, Canada). P.
aeruginosa isolates were subcultured on blood agar plates
and all bacterial deoxyribonucleic acid (DNA) was ex-
tracted using the UltraClean Microbial DNA isolation kit
(MO BIO Laboratories, Carlsbad, CA). DNA strain typing
was performed using the DiversiLab rep-PCR kit for
Pseudomonas fingerprinting (bioMérieux, Durham, NC)
(Fig. 2). The results showed similarities of 90 % to 95 % in
all strains. Although 95 % or greater similarity is generally
accepted as the same strain [3], it seems the result is suffi-
cient for identification as the same strain in all samples
considering epidemiologic circumstances in this case.
Discussion
Patients who have recovered from infective endocarditis
remain at risk for an additional episode of infective endo-
carditis, and the lifetime risk of a second episode of infect-
ive endocarditis has been estimated to be between 2 % and
22 % [4–8]. Repeat infective endocarditis due to the same
species is traditionally defined as a “relapse” if the second
episode of infective endocarditis occurs within 6 months
after the initial episode, but is defined as a “recurrence” if
the second episode occurs after a period greater than 6
months from the previous episode. However, if a repeat
episode of infective endocarditis is shown by molecular
analysis to be caused by the same strain, it would be better
defined as a “relapse” regardless of the time duration be-
tween episodes [1].
In the present case, a non-drug abuser patient suffered
from three repeat attacks of infective endocarditis caused
by the same pathogen, MDR P. aeruginosa, 10 years, 10
months, and 2 months after previous surgery, respectively.
The mechanism for repeat infective endocarditis with
the same pathogen can be categorized as reactivation
of a chronic silent infection (relapse), or a new episode
of infection by a different microorganism (reinfection or
Fig. 1 Echocardiograms performed before the patient’s final discharge (a and b) and 8 months after surgery (c and d). Both showed a
well-functioning aortic valve homograft in the tricuspid position
Fig. 2 The strain typing by automated repetitive sequence-based polymerase chain reaction analysis of all the pathogens (P. aeruginosa) involved
in each event of infective endocarditis of the patient. All the pathogens were shown to have similarities greater than 90 %, and therefore were
identified as the same strain
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serial episodes of infection by genotyping the bacteria.
Based on the automated rep-PCR DNA strain typing re-
sults, all the pathogens were identified as the same strain.
The patient therefore was regarded as having multiple
events of relapsing infective endocarditis, although there
is a hypothetical possibility of reinfection with a persist-
ently colonizing strain.
Because repeated attacks of infective endocarditis oc-
curred due to the same strain of a pathogen which is re-
sistant to multiple antibiotics, we tried to prevent further
recurrence. First, we used colistin as a main antibiotic
therapy because it has been proven to have acceptable ef-
fectiveness on MDR P. aeruginosa [9]. Second, we tried to
remove all abscessed and necrotic tissues intraoperatively
and exposed the tricuspid annulus base so that the previ-
ous abscess site was not concealed by annular sewing su-
tures. Third, we used an aortic homograft for the third
redo-TVR. Completely extirpating the infected tissue and
avoiding placement of any prosthetic material could have
been considered because the previous TVRs with three
different bioprosthetic valves all failed to treat recur-
rent infective endocarditis. However, we decided to use a
homograft because the extirpation procedure could lead
to late-onset right-sided failure in this young woman, and
valve replacement using a homograft is known to be more
resistant to recurrent endocarditis [10].
Conclusions
Based on the automated rep-PCR DNA strain typing re-
sults, all the pathogens in 11 years were identified as the
same strain. The patient therefore can be regarded as
having multiple events of relapsing infective endocarditis
caused by same strain of P. aeruginosa. This is the first
case report of tricuspid valve replacement using an aor-
tic valve homograft to treat relapsing endocarditis.
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